Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review
Open Access
- 30 March 2017
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 8 (6), 197-205
- https://doi.org/10.1177/2040620717699365
Abstract
With a median age of 72 years at first diagnosis, chronic lymphocytic leukaemia (CLL) is a disease of the elderly. At this age, many patients cannot bear an intensive chemoimmunotherapy like fludarabine, cyclophosphamide and rituximab (FCR), and therapeutic decisions are commonly complicated by a high burden of accompanying comorbidities. Clinical trials, on the other hand, are mostly designed to include a far healthier and younger trial population, with a median age in most studies well below 70 years, leading to an insufficient reflection of clinical reality. With the introduction of new targeted therapies, treatment of CLL is currently undergoing a profound change. New compounds like ibrutinib or idelalisib have enlarged the therapeutic options in treating CLL. However, so far, these oral medications imply continuous intake by the patient, which will at some point lead to the issue of adherence in most patients. In addition, long-term experiences are largely missing. In this setting, one of the oldest chemoactive substances remains a viable option for many CLL patients and their treating physicians: bendamustine, a nitrogen–mustard derivative, has proven to be a safe and efficient agent for treatment of CLL in the first- and second-line setting. In particular, there is some evidence that the substance is relatively well tolerated in elderly and unfit patients. In this review, we summarize the current data on bendamustine in the treatment of elderly and unfit patients with CLL and aim to provide a concise analysis and outlook on the current and future role of this substance in the era of new targeted agents.Keywords
This publication has 41 references indexed in Scilit:
- The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemiaAmerican Journal of Hematology, 2013
- Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG)British Journal of Haematology, 2012
- Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins LymphomaClinical Medicine Insights: Oncology, 2011
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2009
- Treatment of elderly patients with chronic lymphocytic leukemiaLeukemia & Lymphoma, 2009
- A Manual of Guidelines to Score the Modified Cumulative Illness Rating Scale and Its Validation in Acute Hospitalized Elderly PatientsJournal of the American Geriatrics Society, 2008
- Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating AgentsClinical Cancer Research, 2008
- Metabolism and mechanisms of action of bendamustine: Rationales for combination therapiesSeminars in Oncology, 2002
- Investigation of cross-link formation in DNA by the alkylating cytostatica IMET 3106, 3393 and 3943Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis, 1972